AcelRx added to the Russell 2000® and 3000® indexes
REDWOOD CITY, Calif., July 1, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Company has been added as a member of the Russell 2000® and Russell 3000® Indexes effective at the opening of trading today, July 1, 2019. "We're pleased to be included in these widely followed indexes which raises our visibility with institutions and investors, and reflects the progress we have made as a commercial stage company," said Vince Angotti, Chief Executive Officer at AcelRx. The annual reconstitution of the Russell indexes captures the 4,000 largest U.S. stocks as of May 10, ranking them by total market capitalization. Membership in the Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell's U.S. indexes. Russell indexes are part of FTSE Russell, a leading global index provider. For more information on the Russell 2000 and 3000 Indexes and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website. About AcelRx Pharmaceuticals, Inc.
View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-added-to-the-russell-2000-and-3000-indexes-300878743.html SOURCE AcelRx Pharmaceuticals, Inc. |
||
Company Codes: NASDAQ-NMS:ACRX |